



## DETECT Endometriosis Imaging Study Presented at EANM'24

London, UK, 23 October 2024. [Serac Healthcare Limited](#) ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that its clinical partner, the [Nuffield Department of Women's and Reproductive Health](#) at the [University of Oxford](#), gave a presentation on the "Detecting Endometriosis expressed integrins using technetium-99m" (DETECT) imaging study at the European Association of Nuclear Medicine (EANM) annual congress taking place from 19-23 October in Hamburg, Germany.

[Dr Tatjana Gibbons](#), an investigator on the study from the University of Oxford gave a Top Rated Oral Presentation on Sunday 20<sup>th</sup> October. The presentation (OP-116) gave an overview of findings from the ongoing DETECT study in which patients with known or suspected endometriosis were imaged with a SPECT-CT camera before planned laparoscopic surgery, a key-hole surgical procedure to establish the presence, absence and location of endometriotic lesions. The imaging findings were then compared to the surgical and histology reports.

The presentation at EANM added to the initial findings as previously presented at two women's health congresses with a focus on endometriosis earlier in the year, indicating that <sup>99m</sup>Tc-maraciclatiside has potential as a non-invasive test for early-stage endometriosis. The presentation at EANM gave the Oxford University team the opportunity to discuss the potential of this molecular imaging agent with this important nuclear medicine audience.

<sup>99m</sup>Tc-maraciclatiside is a radio-labelled tracer which binds with high affinity to the cell adhesion protein  $\alpha_v\beta_3$  integrin and images angiogenesis (new blood vessel formation) which is known to be critical to the establishment and growth of endometriotic lesions.

The ongoing study which will recruit up to 25 patients in total is being led by [Professor Christian Becker](#), Co-Director of the Endometriosis CaRe Centre in Oxford, together with [Professor Krina Zondervan](#), Co-Director of the Endometriosis CaRe Centre and Head of Department at the Nuffield Department of Women's and Reproductive Health, University of Oxford. It is anticipated that the study will complete later this year.

-ENDS-

**Maraciclatiside is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.**

**For more information, please contact:**

**Serac Healthcare Ltd**

[www.serachealthcare.com](http://www.serachealthcare.com)

David Hail, Chief Executive

+44 (0)20 8948 0000

[info@seraclifesciences.com](mailto:info@seraclifesciences.com)

Francetta Carr, Communications

+44 (0)7711 010820

[francettacarr@seraclifesciences.com](mailto:francettacarr@seraclifesciences.com)

**Nuffield Department of Women's and  
Reproductive Health, Oxford University**

[www.wrh.ox.ac.uk](http://www.wrh.ox.ac.uk)

Rob Phillips, Communications

+44 (0)7730 527341

[rob.phillips@wrh.ox.ac.uk](mailto:rob.phillips@wrh.ox.ac.uk)

## Notes to Editors

The abstract titled “**Visualisation of Superficial Peritoneal Endometriosis with <sup>99m</sup>Tc-maraciclalide**” is available in the EANM '24 Abstract book [here](#) (until 7 November 2024) and on our website [here](#).

### About Serac Healthcare Ltd

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

### About the DETECT study

The study is jointly sponsored by the Oxford Endometriosis CaRe Centre and the Nuffield Department of Women's and Reproductive Health, Oxford University, and funded by Serac Healthcare Ltd who are providing the experimental imaging marker <sup>99m</sup>Tc-maraciclalide. Further details are available on ClinicalTrials.gov [here](#).

### About Nuffield Department of Women's & Reproductive Health

The Nuffield Department of Women's & Reproductive Health (NDWRH) at the University of Oxford is a pioneering institution with a rich legacy dating back to 1937; and stands as a vanguard of excellence in perinatal research and clinical practice.

Our vision is clear: a world where everyone enjoys high-quality, evidence-based women's and reproductive healthcare. Through cutting-edge research and transformative teaching, we're committed to elevating the standard and accessibility of women's healthcare worldwide. For further information about NDWRH and its groundbreaking initiatives, please visit <https://www.wrh.ox.ac.uk>

### About endometriosis

Endometriosis is a common inflammatory disease that affects up to one in 10 women of childbearing age, about 190 million women worldwide. Endometriosis occurs when tissue similar to the lining of the uterus is found outside the uterus, predominantly in the pelvis, but sometimes also elsewhere in the body, e.g. lungs. The presence of this ectopic endometrial tissue can lead to inflammation and distortion of normal anatomy, which can cause significant pain and infertility. The diagnostic journey in those with endometriosis typically results in numerous visits to physicians and hospitals, along with multiple scans.

**About EANM'24:** <https://eanm24.eanm.org/>